Novel-agent combination therapies in chronic lymphocytic leukemia: the law of relative contributions

Affiliations

Comment

Anthony R Mato et al. Haematologica. 2022.

. 2022 Sep 1;107(9):2016-2017.

doi: 10.3324/haematol.2021.280217.

No abstract available

Comment on

First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial.
Moreno C, Greil R, Demirkan F, Tedeschi A, Anz B, Larratt L, Simkovic M, Novak J, Strugov V, Gill D, Gribben JG, Kwei K, Dai S, Hsu E, Dean JP, Flinn IW. Moreno C, et al. Haematologica. 2022 Sep 1;107(9):2108-2120. doi: 10.3324/haematol.2021.279012. Haematologica. 2022. PMID: 35021599 Free PMC article. Clinical Trial.

1. Moreno C, Greil R, Demirkan F, et al. . First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial. Haematologica. 2022;107(9):2108-2120. - PMC - PubMed
1. Woyach JA, Ruppert AS, Heerema NA, et al. . Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N Engl J Med. 2018;379(26):2517-2528. - PMC - PubMed
1. Burger JA, Sivina M, Jain N, et al. . Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia. Blood. 2019;133(10):1011-1019. - PMC - PubMed
1. Sharman JP, Egyed M, Jurczak W, et al. . Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial. Lancet. 2020;395(10232):1278-1291. - PMC - PubMed
1. Kater A, Owen C, Moreno C, et al. . Fixed duration ibrutinib and venetoclax (I+V) versus chlorambucil plus obinutuzumab (CLB+O) for first-line (1L) chronic lymphocytic leukemia (CLL): primary analysis of the phase 3 GLOW study. HemaSphere. 2021;5(S2):LB1902.